Stock listing
NASDAQ:YDES YD Bio Limited Stock
Home listing (NASDAQ) of YD Bio Limited
Follow YD Bio Limited into a list and get an email when it puts out news.
Share price · NASDAQ:YDES
$4.83 USD -0.02 (-0.4%)
Close on Nov 20, 2026
- Day range
- $4.36 – $4.95 USDNov 20, 2026
- Volume
- 29,790 sharesNov 20, 2026
- Market cap
- $342.1M USDAt the close on Nov 20, 2026 · price × 70.83M shares outstanding
- 52-week range
- $1.70 – $15.72 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.45M USDMedian day 178,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:YDES · Home | $4.83 USD | -0.02 (-0.4%) | 29,790 | $4.80 | $4.95 | $4.36 | $4.85 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:YDES · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.83 | -0.02 | -0.4% | $4.80 | $4.95 | $4.36 | 29,790 | |
| $4.85 | +0.12 | +2.5% | $4.85 | $5.265 | $4.80 | 21,488 | |
| $4.73 | -0.10 | -2.1% | $4.68 | $5.00 | $4.62 | 35,910 | |
| $4.83 | -0.05 | -1.0% | $5.00 | $5.10 | $4.25 | 120,921 | |
| $4.88 | -0.315 | -6.1% | $5.08 | $5.45 | $4.88 | 25,888 | |
| $5.195 | -0.955 | -15.5% | $6.16 | $6.16 | $5.11 | 79,310 | |
| $6.15 | +0.12 | +2.0% | $6.22 | $6.29 | $6.014 | 13,286 | |
| $6.03 | -0.68 | -10.1% | $6.50 | $6.95 | $5.90 | 103,131 | |
| $6.71 | +0.74 | +12.4% | $6.40 | $6.905 | $6.20 | 40,154 | |
| $5.97 | -1.21 | -16.9% | $7.01 | $7.45 | $5.87 | 206,967 | |
| $7.18 | +0.23 | +3.3% | $6.60 | $7.28 | $6.56 | 76,917 | |
| $6.95 | +0.555 | +8.7% | $6.20 | $7.14 | $6.028 | 81,397 | |
| $6.395 | +0.425 | +7.1% | $5.81 | $6.48 | $5.81 | 22,833 | |
| $5.97 | +0.03 | +0.5% | $5.90 | $6.34 | $5.69 | 180,207 | |
| $5.94 | +0.07 | +1.2% | $5.99 | $6.10 | $5.67 | 47,346 | |
| $5.87 | -0.41 | -6.5% | $6.31 | $6.60 | $5.83 | 96,182 | |
| $6.28 | +0.24 | +4.0% | $6.02 | $6.496 | $5.92 | 283,872 | |
| $6.04 | +0.75 | +14.2% | $5.30 | $6.15 | $5.29 | 47,052 | |
| $5.29 | +0.34 | +6.9% | $5.065 | $5.43 | $4.87 | 59,168 | |
| $4.95 | +0.71 | +16.7% | $4.28 | $5.10 | $4.135 | 105,100 | |
| $4.24 | -1.53 | -26.5% | $5.85 | $6.04 | $4.15 | 180,400 | |
| $5.77 | -0.07 | -1.2% | $5.89 | $6.30 | $5.60 | 144,100 | |
| $5.84 | -0.28 | -4.6% | $6.08 | $6.565 | $5.61 | 178,100 | |
| $6.12 | +0.20 | +3.4% | $5.92 | $6.26 | $5.46 | 92,500 | |
| $5.92 | -0.82 | -12.2% | $6.67 | $7.05 | $5.82 | 153,400 | |
| $6.74 | +0.38 | +6.0% | $6.30 | $6.87 | $6.30 | 72,300 | |
| $6.36 | +0.26 | +4.3% | $6.16 | $6.47 | $6.00 | 20,400 | |
| $6.10 | -0.23 | -3.6% | $6.33 | $6.51 | $6.00 | 23,600 | |
| $6.33 | -0.40 | -5.9% | $7.01 | $7.13 | $6.10 | 138,100 | |
| $6.73 | +0.94 | +16.2% | $5.71 | $7.09 | $5.61 | 207,700 | |
| $5.79 | -0.09 | -1.5% | $5.81 | $6.20 | $5.53 | 149,000 | |
| $5.88 | -0.27 | -4.4% | $6.22 | $6.38 | $5.632 | 135,900 | |
| $6.15 | -0.96 | -13.5% | $6.94 | $7.10 | $5.20 | 439,700 | |
| $7.11 | -1.00 | -12.3% | $7.90 | $8.03 | $6.81 | 258,500 | |
| $8.11 | +0.30 | +3.8% | $7.71 | $8.43 | $6.60 | 546,600 | |
| $7.81 | +0.39 | +5.3% | $7.18 | $8.25 | $6.99 | 267,900 | |
| $7.42 | -0.19 | -2.5% | $7.59 | $7.73 | $6.80 | 205,000 | |
| $7.61 | +0.50 | +7.0% | $7.03 | $7.89 | $6.62 | 347,100 | |
| $7.11 | +1.38 | +24.1% | $6.13 | $7.35 | $5.62 | 507,600 | |
| $5.73 | +0.96 | +20.1% | $4.77 | $5.88 | $4.548 | 654,000 | |
| $4.77 | +1.54 | +47.7% | $3.26 | $5.41 | $3.26 | 3,172,000 | |
| $3.23 | +0.41 | +14.5% | $2.78 | $3.34 | $2.42 | 359,100 | |
| $2.82 | +0.19 | +7.2% | $2.67 | $3.10 | $2.60 | 390,300 | |
| $2.63 | -0.56 | -17.6% | $3.11 | $3.35 | $2.51 | 662,600 | |
| $3.19 | -0.05 | -1.5% | $3.25 | $3.57 | $3.15 | 535,500 | |
| $3.24 | -0.46 | -12.4% | $3.70 | $3.76 | $3.12 | 544,500 | |
| $3.70 | -0.25 | -6.3% | $3.90 | $3.90 | $3.265 | 695,500 | |
| $3.95 | +0.12 | +3.1% | $3.79 | $4.04 | $3.66 | 688,700 | |
| $3.83 | -0.17 | -4.2% | $4.01 | $4.01 | $3.61 | 523,300 | |
| $4.00 | +0.10 | +2.6% | $3.93 | $4.187 | $3.61 | 819,300 | |
| $3.90 | -0.025 | -0.6% | $3.82 | $4.31 | $3.729 | 633,200 | |
| $3.925 | -0.325 | -7.6% | $4.36 | $4.38 | $3.65 | 729,600 | |
| $4.25 | +0.71 | +20.1% | $3.72 | $4.50 | $3.65 | 502,800 | |
| $3.54 | -0.13 | -3.5% | $3.67 | $3.88 | $3.29 | 687,100 | |
| $3.67 | -0.09 | -2.4% | $3.64 | $4.05 | $3.21 | 672,100 | |
| $3.76 | -0.015 | -0.4% | $3.71 | $4.015 | $3.50 | 567,600 | |
| $3.775 | +0.065 | +1.8% | $3.77 | $4.08 | $3.36 | 428,700 | |
| $3.71 | -1.09 | -22.7% | $4.87 | $4.87 | $3.10 | 445,300 | |
| $4.80 | +0.93 | +24.0% | $3.94 | $4.80 | $3.09 | 217,800 | |
| $3.87 | -0.47 | -10.8% | $4.34 | $4.34 | $3.80 | 27,100 | |
| $4.34 | -0.34 | -7.3% | $4.85 | $4.85 | $4.00 | 11,400 | |
| $4.68 | +0.02 | +0.4% | $4.75 | $4.77 | $4.097 | 9,659 | |
| $4.66 | -0.03 | -0.6% | $4.66 | $4.767 | $4.455 | 18,536 | |
| $4.69 | -0.096 | -2.0% | $4.56 | $5.00 | $4.40 | 35,500 | |
| $4.786 | +0.316 | +7.1% | $4.39 | $4.99 | $4.009 | 104,800 |
- Ticker
- NASDAQ:YDES
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease
Latest deck · Jan 15, 2026
Investor Presentation (January 2026)
Investor deck · 26 slides
Latest news
YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease
Nov 12, 2026
Closed $4.88 (-6.1%) on Nov 13, 2026
YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
Oct 20, 2026
Closed $5.84 (-4.6%) on Oct 20, 2026
YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
Oct 6, 2026
Closed $6.15 (-13.5%) on Oct 6, 2026
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
Aug 31, 2026
Closed $3.78 (+1.8%) on Sep 1, 2026
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
Aug 4, 2026
Closed $2.32 (+0.9%) on Aug 4, 2026
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
Jul 28, 2026
Closed $2.30 (+0.4%) on Jul 28, 2026
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
Jul 2, 2026
Closed $1.90 (-17.7%) on Jul 2, 2026
YD Bio Limited Reports Full Year 2025 Financial Results
Apr 30, 2026
Closed $4.80 (-5.9%) on May 1, 2026
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
Mar 31, 2026
Closed $7.70 (-4.9%) on Mar 31, 2026
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
Mar 17, 2026
Closed $7.11 (-8.6%) on Mar 17, 2026
YD Bio Limited on 6ix
- News releases
- 19 in the last 12 months · 24 in all · newest Nov 12, 2026 · oldest 2025
- Decks
- 1 deck · latest Jan 15, 2026
Where YD Bio Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:YDES · Home listing · This page | NASDAQ | United States | USD |
| BOATS:YDES | BOATS | United States | USD |
Valuation
Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $339.5M USD
- P/E
- Loss
- EV/sales
- 569×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 76.5×
- Gross margin
- 28.1%
- Operating margin
- −883.3%
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.25
Team and board
Officers
| Officer | Role |
|---|---|
| Ethan Shen | Chairman & CEO |
| Edmund Hen | CFO |
Board
| Director | Role |
|---|---|
| Ethan Shen | Chairman & CEO |
Events
| Quarter | Results |
|---|---|
| Q1 2025 | Apr 30, 2025 |
| Q3 2024 | Nov 25, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2026) | Investor deck | 26 slides | Jan 15, 2026 |
Financings
| Raise | Date |
|---|---|
| Private placement of pIPE offering securities Closed: private placement Use of proceeds: To fund the Company's future operations | Aug 29, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 596.8K | 510.4K | 350.1K | |||
| Cost of revenue | 429.4K | 355.0K | 196.7K | |||
| Gross profit | 167.4K | 155.4K | 153.4K | |||
| Research and development | 1.60M | 491.4K | 0 | |||
| Selling, general and administrative | 3.82M | 1.12M | 153.1K | |||
| Operating income | -5.27M | -1.46M | -9.85K | -2.32M | -1.72M | -344.2K |
| Depreciation and amortization | 16.2K | 10.2K | 2.45K | |||
| EBITDA | -5.26M | -1.45M | -7.39K | |||
| Interest expense | 0 | 772 | 2.14K | |||
| Income before tax | -8.31M | -1.39M | 17.6K | 3.79M | 8.70M | -2.54M |
| Income tax | -1.53K | 25.1K | 4.09K | 2.09K | ||
| Net income | -8.31M | -1.41M | 13.6K | 3.79M | 8.70M | -2.54M |
| Earnings per share, basic | -0.12 | -0.02 | 0.00 | 0.41 | 0.59 | -0.17 |
| Earnings per share, diluted | -0.12 | -0.02 | 0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 6.01M | 3.13M | 87.1K | 14.1K | 5.40K | 693.8K |
| Receivables | 167.5K | 86.6K | 98.4K | 18.1K | ||
| Inventory | 1.88M | 37.3K | 69.4K | |||
| Current assets | 9.67M | 3.47M | 271.7K | 202.7K | 129.6K | 830.8K |
| Property, plant and equipment | 59.3K | 64.4K | ||||
| Total assets | 13.8M | 6.86M | 321.2K | 17.9M | 118.1M | 117.6M |
| Accounts payable | 413.3K | 26.9K | 18.0K | |||
| Current liabilities | 1.64M | 263.1K | 298.2K | 5.55M | 2.00M | 302.2K |
| Long-term debt | 6.76K | |||||
| Total debt | 6.76K | 22.6K | 47.6K | |||
| Total liabilities | 16.6M | 274.0K | 298.2K | 6.74M | 9.11M | 17.8M |
| Shareholders' equity | -2.86M | 6.59M | 23.0K | 11.2M | 109.0M | 99.8M |
| Shares outstanding | 70.8M | 64.7M | 70.8M | 9.29M | 14.6M | 14.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -6.60M | -1.22M | -55.7K | -3.02M | -688.4K | -253.6K |
| Capital spending | -1.44M | -74.9K | -290 | 0 | -5 | -5 |
| Free cash flow | -8.04M | -1.30M | -55.9K | -3.02M | -688.4K | -253.6K |
| Cash from investing | -1.44M | -2.90M | -290 | 100.4M | -1.15M | -116.7M |
| Cash from financing | 10.9M | 7.11M | 113.9K | -97.3M | 1.15M | 117.7M |
| Share buybacks | -101.5M | |||||
| Change in cash | 2.88M | 3.05M | 57.0K | 8.73K | -688.4K | 693.8K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 31, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Aug 31, 2026 | Current report | SEC |
| 424B3 · Prospectus | Aug 11, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Aug 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
All 80 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jun 1, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | May 26, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Apr 30, 2026 | Current report | SEC |
| 20-F · Annual report | Apr 30, 2026 | Annual report | SEC |
| 3/A · Initial statement of ownership, amended | Apr 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Feb 27, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Feb 26, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 5, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jan 30, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 15, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 15, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 6, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jan 2, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 16, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 17, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Nov 17, 2025 | Current report | SEC |
| F-1/A · Registration statement, amended | Oct 24, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Sep 29, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Sep 26, 2025 | Current report | SEC |
| F-1 · Registration statement | Sep 23, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 19, 2025 | Current report | SEC |
| 20FR12B | Sep 5, 2025 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Aug 28, 2025 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Aug 20, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Aug 15, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 21, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jul 18, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 16, 2025 | Other filings | SEC |
| F-4/A | Jul 15, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 10, 2025 | Other filings | SEC |
| F-4/A | Jul 10, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 7, 2025 | Other filings | SEC |
| F-4/A | Jul 7, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 30, 2025 | Other filings | SEC |
| F-4/A | Jun 30, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 18, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 4, 2025 | Other filings | SEC |
| F-4/A | Jun 4, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 30, 2025 | Other filings | SEC |
| F-4/A | Apr 30, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 17, 2025 | Other filings | SEC |
| F-4/A | Mar 17, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Feb 14, 2025 | Other filings | SEC |
| F-4/A | Jan 30, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 16, 2025 | Other filings | SEC |
| SEC STAFF ACTION | Jan 13, 2025 | Other filings | SEC |
| F-4/A | Dec 20, 2024 | Offer document | SEC |
| F-4/A | Dec 17, 2024 | Offer document | SEC |
| F-4 | Nov 25, 2024 | Offer document | SEC |
| 425 | Jun 21, 2024 | Other filings | SEC |
| 425 | Mar 20, 2024 | Other filings | SEC |
| 425 | Mar 15, 2024 | Other filings | SEC |
| S-4 · Registration statement | Feb 14, 2024 | Offer document | SEC |
Cap table
Built by 6ix from YD Bio Limited’s releases · as of Aug 29, 2025
- Common shares
- 70,831,346
- Fully diluted
- 70,831,346
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 70,831,346 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 70,831,346 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ethan Shen Other companies: SL Science Holding Ltd (Chief Technology Officer (CTO) · Since at least Jun 12, 2026); Horizon Space Acquisition II Corp. (Chief Technology Officer (CTO) · Since at least May 12, 2025) | Chairman & CEO · Since at least Mar 18, 2026 |
| Bo-Xiang Zhang | Chief Medical Officer, Director · Since at least Mar 18, 2026 |
| Edmund Hen | CFO · Since at least Nov 5, 2026 |
| Jerry Yin-Chia Lee | Director · Since at least Mar 18, 2026 |
| Kochi Chang | Director · Since at least Mar 18, 2026 |
| Man Edmund Hen | Chief Financial Officer · Since at least Mar 18, 2026 |
| Shao-Ta Lu | Director · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about YD Bio Limited.